Gastroesophageal Reflux Disease-related Symptom Assessment in Subjects with XXXX Receiving Esophageal Stents.

@entity1 @entity5 @entity158 @entity1282 @entity354 @entity420
Concerns remain over the ability to stent across of the lower esophageal sphincter (LES) for @entity420 and the effects of gastroesophageal (GE) reflux. Thus, the aim of this study was to demonstrate minimal quality-of-life (QOL) side effects in @entity1 undergoing esophageal stenting across the LES. An Institutional Review Board-approved prospective clinical trial evaluated the results of the Gastrointestinal Symptom questionnaire that includes a @entity354 ( @entity354 ) assessment ( @entity354 -HRQL) and a @entity1282 assessment. Consecutive @entity1 were enrolled in this clinical trial, with 81 per cent male, 19 per cent female, median age of 62 years, with @entity420 as their diagnosis. The median @entity1282 score was 3 (only liquids can be tolerated) prestent and was improved to a median score of 0 (ability to eat all foods) poststent (P = 0.01). The median @entity354 score was 0 (none) prestent and did not change with a median score of 0 (none) poststent (P = 0.2). All @entity354 -related questions were unchanged prestent and poststent in all categories, specifically: frequency of @entity354 , time of day of reflux, @entity158 behind breastbone, and @entity158 medications. There was also no difference in regurgitation frequency (median prestent 1 vs poststent 0, P = 0.08), texture (prestent 2 [semisolid] vs poststent 1 [liquid]). There was only a statistical change in the ability to belch (prestent 0 [no ability] to poststent 1 [ability]), P = 0.02) and the ability to vomit. Esophageal stenting across the GE junction for @entity1282 relief in @entity5 does not adversely effect a @entity1 's QOL in regard to reflux-related symptoms.
